Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?
ALOE VERA ROLE IN WINNING SOLUTIONS' ATHLETE'S FOOT PRODUCT
ALOE VERA ROLE IN WINNING SOLUTIONS' ATHLETE'S FOOT PRODUCT is the "most important issue to be resolved" before the company begins a low-dose tolnaftate clinical study, FDA told Winning Solutions in a May 20 letter. Responding to a citizen's petition submitted by the company in January to support the use of a lower concentration of tolnaftate for athlete's foot (tinea pedis) than the 1% allowed in the September 1993 OTC topical antifungals final monograph, the agency noted that Winning Solutions has to first determine whether the 60% aloe vera base of its product serves as an inactive vehicle or an adjuvant in the formulation.
More from Archive
• By
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
• By
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
• By
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
• By
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
• By
Companies in Europe cannot delay business decision making much longer to wait for more certainty on major US policy shifts on tariffs and pricing.
• By
Stay up to date on regulatory guidelines from around the world with the Pink Sheet’s Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
• By
Following EU approval of the first disease-modifying treatment for Alzheimer’s disease, and with a second expected soon, the European Medicines Agency plans to update its guidance to support the design of state-of-the-art clinical trials for the disease and enhance drug development.